Lindy Fishburne
Managing Partner & Founder @ Breakout Ventures
San Francisco, United States
Lindy Fishburne is a seed investor at Breakout Ventures in San Francisco focused on Biotechnology and Chemical. Lindy Fishburne is the Managing Partner of Breakout Ventures and the Founder of Breakout Labs, the seed-stage program for hard science at the Thiel Foundation. For the last 8 years, she has been investing at the intersection of technology and biology. She attended Duke University and The University of Texas at Austin.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Lindy Fishburne invests in
Stages Lindy Fishburne invests in
Countries Lindy Fishburne invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Chemical 2 (29%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Manufacturing 2 (29%)
Stage
- Seed 3 (43%)
- Series A 3 (43%)
- Grant 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AquaPoro is a Developer of atmospheric water-generating devices intended to break through materials science for industrial-scale moisture capture in arid environments. The company's proprietary technology is poised to transform global water infrastructure, creating a more resilient and sustainable future for our planet, enabling customers toproduce clean water from vapor. | $5M / Seed / Jun 24, 2026 | ||
| Copernic Catalysts develops sustainable chemical catalysts and processes. | $8M / Seed / Nov 12, 2024 | ||
| The world they live in is built from petroleum. The paints on their walls, the carpets in their homes, the tires on their cars, the plastics for everyday consumer goods – these and many more products are made from chemicals that are mostly made from petroleum, creating a $3 trillion/yr industry. To fulfill their dependency on petroleum, theydo crazy things like setting up oil rigs in the middle of the ocean and drilling several miles into the ocean floor! They’ve done these things because they have had no alternative to meet their needs. Not anymore!Over the past decade, advances in engineering microorganisms have afforded us the opportunity to make the same chemicals that are traditionally made from petroleum. Instead of requiring raw materials buried deep within the earth, microbes can use abundant and renewable sources of carbon such as sugars during processes akin to brewing beer. Despite the numerous advantages, making chemicals this way at the industrial level is still rare. This is because it’s still more expensive than using petroleum for producing the chemicals. Although a few challenges need to be solved to usher in the era of renewable chemicals, a fundamental constraint that limits the economic competitiveness of using microbes is the loss of at least 33% of the carbon as carbon dioxide waste during the fermentation – think of this as the head on your beer. Because of this carbon loss, potential product is simply not made. In technical terms, the maximum achievable yields are 67%. As sugars are the most expensive component of a bioprocess, making the carbon dioxide waste translates to as much as 20% of total costs, which severely hampers the economics of the bioprocess and its competitiveness with petroleum-based production methods.At ZymoChem, they are re-imagining the microbe, one that is designed to eliminate (or substantially reduce) carbon loss during the production of chemicals. To do this, they had to design a completely new biosynthetic pathway – one that doesn’t exist in nature – to make the chemicals. Each individual step of this pathway is designed to not lose carbon as carbon dioxide, enabling their biosynthetic pathway to retain all of the sugar’s carbon into the final chemical product. This carbon conservation allows their approach to have superior theoretical yields, up to 50% better than existing state-of-the-art technology! In turn, their technology has the potential to substantially lower production costs and drastically improve cost-competitiveness for making a variety of chemicals from renewable sources, even at today's oil prices. | $21M / Series A / Jan 15, 2024 | ||
| A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that proteininteractions are measured.A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. | $22.4M / Series A / Jul 25, 2023 | ||
| Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. | $16M / Seed / Apr 12, 2022 | ||
| ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany. | $3M / Series A / Mar 26, 2020 | ||
| Siva Therapeutics Inc., a biotechnology company, engages in the development of nanotechnology approaches for the treatment of cancer. It develops SivaRods, a photo thermal device, which uses heat to irreversibly damage solid tumor tissues. The company was founded in 2011 and is based in Boulder, Colorado. | $350K / Grant / Sep 26, 2012 |
Co-Investors
About Breakout Ventures
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Breakout Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dana Watt
Principal
|
|||
|
Lindy Fishburne
Managing Partner & Founder
|
|||
Nima Ronaghi
Associate
|
|||
Renee Shenton
Head of Community
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lindy Fishburne invest in?
Lindy Fishburne invests primarily in Biotechnology, Chemical and Health Care startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lindy Fishburne?
Public channels for Lindy Fishburne include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Lindy Fishburne last invest?
The most recent investment recorded for Lindy Fishburne closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
